FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Factor patents



      
           
This page is updated frequently with new Factor-related patent applications. Subscribe to the Factor RSS feed to automatically get the update: related Factor RSS feeds. RSS updates for this page: Factor RSS RSS


Date/App# patent app List of recent Factor-related patents
07/17/14
20140201864
 Polynucleotides and polypeptides in plants patent thumbnailnew patent Polynucleotides and polypeptides in plants
The invention relates to plant transcription factor polypeptides, polynucleotides that encode them, homologs from a variety of plant species, and methods of using the polynucleotides and polypeptides to produce transgenic plants having advantageous properties compared to a reference plant. Sequence information related to these polynucleotides and polypeptides can also be used in bioinformatic search methods and is also disclosed..
07/17/14
20140201861
 Polynucleotides and polypeptides that confer increased yield, size or biomass patent thumbnailnew patent Polynucleotides and polypeptides that confer increased yield, size or biomass
The present description relates to plant transcription factor polypeptides, polynucleotides that encode them, homologs from a variety of plant species, and methods of using the polynucleotides and polypeptides to produce transgenic plants having advantageous properties compared to a reference plant, including the traits of increased yield, size or biomass.. .
07/17/14
20140199679
 Bioreactor patent thumbnailnew patent Bioreactor
A bioreactor for the formation of mature blood cells from haematopoietic stem cells is disclosed. The bioreactor comprises a first zone and a second zone.
07/17/14
20140199377
 Multiple growth factor compositions, methods of fabrication, and methods of treatment patent thumbnailnew patent Multiple growth factor compositions, methods of fabrication, and methods of treatment
Disclosed are compositions with sustained-release carriers associated with at least two different types of growth factors and methods of fabrication and treatments thereof. In some embodiments, simultaneous release of the growth factors may be preferred while in other embodiments, sequential release of the growth factors may be preferred.
07/17/14
20140199372
 Microbial growth factors patent thumbnailnew patent Microbial growth factors
Disclosed are methods of cultivating or isolating a microorganism using one or more quinones as growth factors. Also disclosed are methods of treating a mammalian species with deficiency in symbionts using such compounds..
07/17/14
20140199361
 Inhibitory anti-factor xii/xiia monoclonal antibodies and their uses patent thumbnailnew patent Inhibitory anti-factor xii/xiia monoclonal antibodies and their uses
The invention relates to inhibitory anti-factor xii/fxiia antibodies and methods of their use.. .
07/17/14
20140199301
 Recombinant antibody structures binding to and blocking the activity of vascular endothelial growth factor 2 (vegfr- 2/kdr) patent thumbnailnew patent Recombinant antibody structures binding to and blocking the activity of vascular endothelial growth factor 2 (vegfr- 2/kdr)
Phage displayed recombinant antibody library was developed and the library was screened against vegfr-2. After screening and elisa experiments two recombinant antibodies showing binding properties to vegfr-2 was obtained.
07/10/14
20140196162
 Plant transcriptional regulators patent thumbnailPlant transcriptional regulators
The invention relates to plant transcription factor polypeptides, polynucleotides that encode them, homologs from a variety of plant species, and methods of using the polynucleotides and polypeptides to produce transgenic plants having improved tolerance to drought, shade, and low nitrogen conditions, as compared to wild-type or reference plants.. .
07/10/14
20140196161
 Transgenic plants with enhanced agronomic traits patent thumbnailTransgenic plants with enhanced agronomic traits
This invention provides recombinant dna for expression of proteins that are useful for imparting enhanced agronomic trait(s) to transgenic crop plants. Also provided by this invention is transgenic seed for growing a transgenic plant having recombinant dna in its genome and exhibiting an enhance agronomic trait, i.e.
07/10/14
20140195686
 Optimized consistent request distribution for balanced load distribution in a content delivery network patent thumbnailOptimized consistent request distribution for balanced load distribution in a content delivery network
Some embodiments provide a proprietary 64-bit consistent distribution scheme that preserves the efficiencies of carp while providing a significantly more balanced distribution of requests that is on par with schemes reliant on computationally expensive cryptographic hashes. The scheme performs hashing of requested urls and identifiers of available servers over a 64-bit space while optimizing the hashing to remove computationally expensive operations.
07/10/14
20140195264
Chronic population based cost model to compare effectiveness of preventive care programs
Our invention is a cost model for healthcare, based not on “age”, as it is done currently, but on “chronic illness” as a risk factor. Using the model it is possible to derive two burden numbers, “primary” and “secondary” that is an inverse measure of the success of primary and secondary preventive care programs.
07/10/14
20140195211
Topography simulation apparatus, topography simulation method and recording medium
In one embodiment, a topography simulation apparatus includes a division module to divide a substance surface into plural computing elements, a determination module to extend straight lines in plural directions from each computing element, and to determine whether each straight line contacts the substance surface and determine which computing element each straight line contacts, and a calculation module to calculate, based on results of the determinations, a direct flux of a reactive species directly reaching each computing element, and a form factor indicating a positional relationship between the computing elements. When the determinations are performed to calculate the form factor in a case where an ionic species reaching each computing element is reflected, the determinations are performed by setting a cut-off angle for a reflection direction of the ionic species, and limiting the directions in which the straight lines are extended within a range of the cut-off angle..
07/10/14
20140194600
Use of anti-factor xi antibodies for prevention of thrombus formation
The present invention relates to binding molecules such as antibodies that specifically bind plasma coagulation factor xi and that inhibit factor xi activation and/or activity. The factor xi-binding molecules of the invention may used in methods for preventing or treating diseases, disorders and/or conditions that are mediated by factor xi activation and/or wherein inhibition of factor xi has a beneficial effect..
07/10/14
20140194352
Compositions and methods for treatment of metabolic disorders and diseases
The invention relates to variants and fusions of fibroblast growth factor 19 (fgf19), variants and fusions of fibroblast growth factor 21 (fgf21), fusions of fibroblast growth factor 19 (fgf19) and/or fibroblast growth factor 21 (fgf21), and variants or fusions of fibroblast growth factor 19 (fgf19) and/or fibroblast growth factor 21 (fgf21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.. .
07/10/14
20140193899
Monoclonal antibodies to fibroblast growth factor receptor 2
The present invention is directed toward a monoclonal antibody to fibroblast growth factor receptor 2, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.. .
07/10/14
20140193880
Modified factor viii and factor ix genes and vectors for gene therapy
The present invention relates to a modified and optimized factor viii or factor ix nucleic acid for inclusion in a chimeric virus vector. Use of such vector can be used for treatment of hemophilia..
07/10/14
20140193846
Novel apoc-i isoforms and their use as biomarkers and risk factors of atherosclerotic disease
Novel isoforms of apolipoprotein c-i (apoc-i), namely apolipoprotein c-i1 (apoc-i1) and apolipoprotein c-i1′ (apoc-i1′), both of which have a molecular weight of approximately 90 daltons greater than native apolipoprotein c-i (seq id no:6) and native apolipoprotein c-i′ (seq id no:7), are shown to be both biomarkers for diagnosing atherosclerotic disease as well as risk factors for subjects having increased risk of developing an atherosclerotic disease.. .
07/10/14
20140193441
Method of administering porcine b-domainless fviii
The present invention provides a method of administering porcine b-domainless factor viii (obi-1) to a patient having factor viii deficiency to provide more rapid and effective protection against bleeding episodes, compared to formerly available methods, or to provide more effective protection to such patients during non-bleeding periods. This invention is based on the discovery that the recombinant b-domainless porcine fviii, termed obi-1, has greater bioavailability compared to the natural porcine fviii partially purified from porcine plasma, termed hyate:c.
07/10/14
20140193411
Multimeric constructs
Multimeric fusion proteins of an ig-like domain of flt-1 are rendered functional by inclusion of a linker moiety. Vectors encoding the fusion proteins and host cells expressing the fusion proteins can be used therapeutically to block neovascularization in individuals with pathological conditions related to neovascularization.
07/10/14
20140193402
Anti-pdgfr-beta antibodies and uses thereof
The present invention provides antibodies that bind to platelet derived growth factor receptor beta (pdgfr-beta) and methods of using the same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human pdgfr-beta with high affinity.
07/10/14
20140193334
Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof
Acridine containing cisplatin compounds have been disclosed that show greater efficacy against cancer than other cisplatin compounds. Methods of delivery of those more effective cisplatin compounds to the nucleus in cancer cells is disclosed using one or more amino acids, one or more sugars, one or more polymeric ethers, c1-6alkylene-phenyl-nh—c(o)—r15, folic acid, αvβ3 integrin rgd binding peptide, tamoxifen, endoxifen, epidermal growth factor receptor, antibody conjugates, kinase inhibitors, diazoles, triazoles, oxazoles, erlotinib, and/or mixtures thereof; wherein r15 is a peptide..
07/10/14
20140192811
Method and a device for defining a look-up system for a network element of a software-defined network
A method for defining a look-up system having functionality suitable for a network element of a software-defined network “sdn” includes maintaining (401) data specifying a set of look-up tables so that the look-up system is capable of being constructed in alternative ways using one or more look-up tables of the set of look-up tables and each of the look-up tables has a look-up table specific resource consumption estimate indicating a load factor of at least one component of the network element when running operations related to the look-up table. The method includes selecting (402), on the basis of the look-up table specific resource consumption estimates, such one of the alternative ways of constructing the look-up system which provides a look-up system that is optimal, or at least suitable, for the network element..
07/10/14
20140192683
Method and a controller system for configuring a software-defined network
A method for configuring a network element of a software-defined network “sdn” includes retrieving (401), for different look-up tables, a look-up table specific resource consumption estimate indicating a load factor of at least one component of the network element when running operations related to the look-up table, determining (402), on the basis of the look-up table specific resource consumption estimates, a resource consumption estimate for at least one look-up system including one or more of the look-up tables and having functionality suitable for the network element, and sending (404) to the network element, if the network element is capable (403) of running the look-up system, configuration data defining the look-up system. The method provides a possibility to avoid configuring network elements to overload and, on the other hand, the resource consumption estimates related to different network elements can be used for optimizing the software-defined network as a whole..
07/03/14
20140189556
Augmented i/o for limited form factor user-interfaces
The claimed subject matter relates to an architecture that can enhance and/or simplify tactile-based i/o transactions in connection with a user-interface (ui) of limited form factor. In particular, the architecture can monitor a position of a selector object such as an operator's finger relative to a ui display as the selector object hovers or moves above the ui display.
07/03/14
20140188402
Outlier detection for analyte sensors
Systems and methods for processing sensor data and end of life detection are provided. In some embodiments, a method for determining the end of life of a continuous analyte sensor includes evaluating a plurality of risk factors using an end of life function to determine an end of life status of the sensor and providing an output related to the end of life status of the sensor.
07/03/14
20140188033
Drug delivery using a sacrificial host
Implantable drug-doped component, e.g., a cochlear implant, including host material, a host-embedded drug, a sacrificial material integrated with the host. Sacrificial material facilitates release of drug from the component.
07/03/14
20140188007
Small form factor medical sensor structure and method therefor
A measurement system for measuring a parameter of the muscular-skeletal system is disclosed. The measurement system comprises a capacitor, a signal generator, a digital counter, counter register, a digital clock, a digital timer, and a data register.
07/03/14
20140187639
Small molecule antagonists of phosphatidylinositol-3,4,5-triphosphate (pip3) and uses thereof
Disclosed are new members of a class of non-lipid small molecule inhibitors which interfere with the interaction between phosphoinositol-3,4,5-triphosphate (pip3) and pleckstrin homology (ph) domains. These molecules target a broad range of pip3-dependent signaling events in vitro and exert significant anti-tumor activity in vivo, with improved activity and selectivity toward particular ph domains.
07/03/14
20140187610
Connective tissue growth factor antisense oligonucleotides
The present invention relates to antisense oligonucleotides that target human ctgf mrna and inhibit ctgf mrna expression. Additionally, regions of human ctgf mrna that are exceptionally sensitive to antisense inhibition are disclosed.
07/03/14
20140187563
Combination therapy in treatment of oncological and fibrotic diseases
The invention relates to new methods for the treatment of oncological and fibrotic disease comprising the combined administration of an inhibitor of vascular endothelial growth factor receptors (vegfrs) in conjunction with a thrombin inhibitor.. .
07/03/14
20140187559
Inhibitors of the fibroblast growth factor receptor
Described herein are inhibitors of fgfr, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of tyrosine kinases.. .
07/03/14
20140186947
Activation and expansion of t-cells using an engineered multivalent signaling platform as a research tool
Provided are a system and methods for selectively inducing expansion of a population of t cells in the absence of exogenous growth factors, such as lymphokines, and accessory cells for research purposes. The cell based expansion system and methods permit the long-term growth of ctls, preferably human ctls.
07/03/14
20140186864
Method for identifying a malodor inhibitor
Provided is a method for identifying a malodor inhibitor based on a response of an olfactory receptor. The present invention provides a method for identifying a malodor inhibitor including: adding a test substance and a malodor-causing substance to at least one olfactory receptor selected from the group consisting of or5p3, or5k1, or2w1, or8h1, and a polypeptide which has 80% or more identity in amino acid sequence to any one of the aforementioned polypeptides; measuring the response of the olfactory receptor to the malodor-causing substance; identifying the test substance which can suppress the response of the olfactory receptor based on the measured response; and selecting, as a malodor inhibitor, the test substance which can suppress the response of the olfactory receptor..
07/03/14
20140186435
Soluble tumor necrosis factor receptor (stnf-r) used as a targeting agent to treat arthritis and other diseases
This invention describes the use of stnf-r as a targeting agent attached to liposomes incorporating anti-inflammatory drugs to treat arthritis and other inflammatory diseases. A variety of steroidal and non-steroidal drugs and disease modifying drugs and other anti-inflammatory compounds may be incorporated into the stnf-r coated liposomes.
07/03/14
20140186434
Anti-tumor necrosis factor alpha (tnf-a) antibody used as a targeting agent to treat arthritis and other diseases
This invention describes the use of anti-tnf-a antibody as a targeting agent attached to liposomes incorporating anti-inflammatory drugs to treat arthritis and other inflammatory diseases. A variety of steroidal and non-steroidal drugs and disease modifying drugs and other anti-inflammatory compounds may be incorporated into the anti-tnf-a coated liposomes.
07/03/14
20140186381
Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides
The present invention provides immunogenic peptides comprising the amino acid sequence of seq id no: 1, 2, 13, 32, and peptides comprising the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted or added, and having cytotoxic t cell inducibility, and also provides drugs for treating or preventing tumors comprising these peptides. The peptides of this invention can be used as vaccines..
07/03/14
20140186368
Methods of administering anti-tnfalpha antibodies
Methods of treating disorders in which tnfα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (htnfα) are disclosed. The antibody may be administered with or without methotrexate.
07/03/14
20140186327
Coagulation factor ix compositions and methods of making and using same
The present invention relates to compositions comprising factor ix coagulation factors linked to extended recombinant polypeptide (xten), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of coagulation factor-related diseases, disorders, and conditions.. .
07/03/14
20140186323
Factor viia-polysialic acid conjugates having prolonged in vivo half-life
The present invention relates to a proteinaceous construct comprising plasmatic or recombinant factor viia (fviia) or biologically active derivatives thereof, which are bound to a carbohydrate moiety comprising 1-4 sialic acid units, wherein the in vivo half-life of the proteinaceous construct is substantially prolonged in the blood of a mammal, as compared to the in vivo half-life of a fviia molecule not bound to a carbohydrate moiety. The invention also provides a method for controlling bleeding in a mammal having a bleeding disorder due to functional defects or deficiencies of fviia, fviii, or fix.
07/03/14
20140185855
Headphone device
A headphone device includes a first audio output module, a second audio output module, and a head module connected between the first and second audio output modules that are located at both ends of the head module respectively. The head module stays bent when in use and stays straight when in compact storage.
07/03/14
20140182350
End of life detection for analyte sensors
Systems and methods for processing sensor data and end of life detection are provided. In some embodiments, a method for determining the end of life of a continuous analyte sensor includes evaluating a plurality of risk factors using an end of life function to determine an end of life status of the sensor and providing an output related to the end of life status of the sensor.
06/26/14
20140180699
Advanced risk stratification for clinical decision support
Systems, methods, and user interfaces for providing dynamic risk stratification for clinical decision support are provided. Selections of patient types are received for patients.
06/26/14
20140180480
Comfort control system, user-end subsystem thereof, and system-end device thereof
A comfort control system includes a user-end subsystem and a system-end subsystem. The user-end subsystem includes an environmental control device, a sensor and a communication apparatus.
06/26/14
20140180399
Mesh enclosed tissue constructs
Described is a heart valve leaflet manufactured from a mesh material. The mesh material may have an ability to capture circulatory/stationary/migratory cells of the body to become biologically active.
06/26/14
20140179940
Methods and compositions for improved production of fatty acids and derivatives thereof
The invention relates to compositions and methods, including polynucleotide sequences, amino acid sequences, and engineered host cells for producing fatty acids and derivates of fatty acids such as acyl-coa, terminal olefins, fatty aldehydes, fatty alcohols, alkanes, alkenes, wax esters, ketones and internal olefins through altered expression of the transcription factor, fadr.. .
06/26/14
20140179896
Inhibitors of type 2 vascular endothelial growth factor receptors
The present disclosure relates to novel vascular endothelial growth factor receptor (vegfr)-binding polypeptides and methods for using these polypeptides to inhibit biological activities mediated by vascular endothelial growth factors (vegfs). The present disclosure also provides various improvements relating to single domain binding polypeptides..
06/26/14
20140179737
Piperidine-2, 6-dione derivatives and their use as tumor necrosis factor inhibitors
Wherein n represents 1, 2, 3, 4, 5 or 6; r1 represents from one to four of the same or different substituents selected from f, cl, br, c1-4 alkyl, oh, oc1-4 alkyl, no2, nhc(o)c1-4 alkyl, nh2, nh(c1-4 alkyl), n(c1-4 alkyl)2; r2 represents or3, nr3r4, n(r3)cor4, o2cr5; r3 and r4 represent independently and at each occurrence h or c1-4 alkyl; r5 represents chr6nr7r8, chr6nr9c(o)chr10nr7r8, a heterocycle w or chr6nr9c(o)w; r6, r9, r10 represent independently and at each occurrence h, or c1-4 alkyl; r7 and r8 represent independently and at each occurrence h, c1-4 alkyl, or r7 and r8 taken together represent 1,3-propylene, 1,4-butylene, 1,5-pentylene, or 1,6-hexylene; w represents four-membered, five-membered, six-membered, seven-membered, or eight-membered saturated or unsaturated heterocycle.. .
06/26/14
20140178986
Soluble inhibitors of vascular endothelial growth factor and use thereof
The present invention relates to cdna encoding a soluble neuropilin protein (snp) which is isolated from neuropilin (np) producing cells or is recombinantly engineered from np-encoding dna. Np-1 and np-2 are preferred nps but any neuropilin or vegf receptor (vegfr), where the constituents share at least about 85% homology with either of the above vegf165r/np-1 and np-2.
06/26/14
20140178935
Hepatocyte growth factor (hgf) binding proteins
The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (hgf), in particular human hgf. The binding proteins can be used as diagnostic and/or therapeutic agents.
06/26/14
20140178934
Hepatocyte growth factor (hgf) binding proteins
The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (hgf), in particular human hgf. The binding proteins can be used as diagnostic and/or therapeutic agents.
06/26/14
20140178898
Method for detecting fat-reducing compounds
A method for detecting fat-reducing compounds comprises four steps, the first step is to provide a clone of adipocytes cultured on a culture dish; the second step is to add a dilution of a test compound to the culture dish for a first time; the third step is to add an insulin-like growth factor to the culture dish for a second time; and the fourth step is to collect the adipocytes for detecting the expression level of at least one specific protein to be a reference value for reducing fat or for decreasing the glucose transport by the test compound. A further method for detecting fat-reducing compounds is disclosed by modifying the last step which detects the levels of a particular protein translocated from the cytosol to the cell membrane of the adipocytes for testing whether the compounds have the ability to regulate or reduce adipocyte glucose uptake..
06/26/14
20140178510
Extract of adlay bran and uses thereof
The present invention provides a composition comprising extract of adlay bran, wherein the adlay bran extract comprises c1 to c7 alcohol extract of adlay bran (a) and carbon dioxide supercritical fluid extract of adlay bran (b). Preferably, the extract of adlay bran has effects in treating a skin and/or subcutaneous tissue disease and in lowering interleukin (il)-1α, interleukin-1β, interleukin-6, tumor necrosis factor (tnf)-α, interleukin-8, prostaglandin-2 (pge2) and/or c-reactive protein (crp)..
06/26/14
20140178356
Stabilised solid compositions of factor vii polypeptides
The invention relates to chemically as well as physically stable compositions comprising factor vii or a factor vii-related polypeptide such that these compositions can be stored, handled and used at room temperature.. .
06/26/14
20140178339
Insulin-like growth factor binding protein 7 for treatment of cancer
Methods of treating a tumor in a subject include identifying a subject having, at risk for, or suspected of having a tumor, and administering to the subject an effective amount of an igfbp7 agent if the tumor has increased ras-braf-mek-erk signaling, is dependent for growth and/or survival upon the ras-braf-mek-erk signaling pathway, and/or expresses an activated or oncogenic braf or ras.. .
06/26/14
20140178307
Methods and assays for treating subjects with shank3 deletion, mutation or reduced expression
Methods and assays are disclosed for treating subjects with 22q13 deletion syndrome or shank3 deletion or duplication, mutation or reduced expression, where the methods comprise administering to the subject insulin-like growth factor 1 (igf-1), igf-1-derived peptide or analog, growth hormone, an ampakine, a compound that directly or indirectly enhances glutamate neurotransmission, including by inhibiting inhibitory (most typically gaba) transmission, or an agent that activates the growth hormone receptor or the insulin-like growth factor 1 (igf-1) receptor, or a downstream signaling pathway thereof.. .
06/26/14
20140178015
Fiber optic cable with electrical connectors at both ends, wall plates and control boxes
A connecting device for a fiber optic cable includes a first part having first and second electrical connectors located on its housing, and a second part having a third electrical connector located on its housing. The second and third electrical connectors are adapted to be mechanically and electrically connect with each other or disconnected from each other.


Popular terms: [SEARCH]



Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Factor for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Factor with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.2746

3827

2 - 1 - 76